Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cefpodoxime/ETX 0282 - Entasis Therapeutics

Next Previous
Drug Profile

Cefpodoxime/ETX 0282 - Entasis Therapeutics

Alternative Names: ETX 0282/Cefpodoxime - Entasis Therapeutics; ETX0282CPDP

Latest Information Update: 28 Sep 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AstraZeneca
  • Developer Entasis Therapeutics
  • Class Anti-infectives; Antibacterials; Cephalosporins; Heterocyclic bicyclo compounds; Urinary anti-infective agents
  • Mechanism of Action Beta lactamase inhibitors; Cell wall inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Urinary tract infections

Most Recent Events

  • 28 Sep 2024 No recent reports of development identified for preclinical development in Urinary-tract-infections(Complicated) in Australia (PO, Controlled release)
  • 28 May 2023 No recent reports of development identified for phase-I development in Urinary-tract-infections(In volunteers, Complicated) in Australia (PO, Capsule)
  • 07 May 2021 Cefpodoxime/ETX 0282 is still in phase-I clinical trials in Urinary tract infections in Australia (PO) (Entasis Therapeutic pipeline, May 2021)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top